Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GT Metabolic Solutions has developed and clinically validated a minimally invasive, incisionless magnetic compression system for gastrointestinal anastomoses. The first-generation MagDI™ System received FDA De Novo marketing authorization in 2024 after successful multi-center clinical trials demonstrating efficacy and safety in side-to-side duodeno–ileal anastomosis during bariatric surgery. Early results show durable weight loss and improved glycemic control with reduced complications compared to traditional methods. Second-generation devices are currently under clinical investigation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GT Metabolic Solutions.